Revenue
2018
2019
2020
2021
2022
2023
2024
2025
REGENXBIO Inc. (RGNX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M | $470.3M | $154.6M | $35.2M | $218.5M | $10.4M | $4.6M | $7.6M | $6.1M | $6.1M |
| Research & development | $228.3M | $208.5M | $232.3M | $242.5M | $181.4M | $166.3M | $124.2M | $83.9M | $57.2M | $45.5M | $17.3M | $5.0M | $5.1M |
| Operating income | −$161.2M | −$233.3M | −$268.1M | −$262.9M | $160.0M | −$119.2M | −$149.0M | $88.1M | −$75.9M | −$65.3M | −$23.1M | −$3.7M | −$4.8M |
| EBITDAderived | −$145.6M | −$217.1M | −$250.8M | −$250.0M | $169.5M | −$110.8M | −$141.8M | $92.1M | −$73.2M | −$64.8M | −$23.1M | −$3.7M | −$4.8M |
| Net income | −$193.9M | −$227.1M | −$263.5M | −$280.3M | $127.8M | −$111.3M | −$94.7M | $99.9M | −$73.2M | −$63.0M | −$22.8M | −$4.0M | −$5.4M |
| Basic EPSper diluted share | -$3.76 | -$4.59 | -$6.02 | -$6.50 | $3.01 | -$2.98 | -$2.58 | $2.99 | -$2.45 | -$2.38 | -$2.59 | -$1.82 | -$2.50 |
| Diluted EPSper diluted share | -$3.76 | -$4.59 | -$6.02 | -$6.50 | $2.91 | -$2.98 | -$2.58 | $2.73 | -$2.45 | -$2.38 | -$2.59 | -$1.82 | -$2.50 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 11, 2026Form 4 · 10b5-1 | PAKOLA STEVEChief Medical Officer | SellCommon Stock | 15.3K | $11.02 | $168.7K | 232.6K |
| Mar 10, 2026Form 4 · 10b5-1 | PAKOLA STEVEChief Medical Officer | SellCommon Stock | 5.1K | $10.35 | $53.0K | 247.9K |
| Oct 9, 2025Form 4 · 10b5-1 | Simpson CurranChief Executive Officer | SellCommon Stock | 20.8K | $12.62 | $262.6K | 216.2K |
| Sep 29, 2025Form 4 · 10b5-1 | Simpson CurranChief Executive Officer | SellCommon Stock | 7.6K | $10.03 | $76.5K | 237.0K |
| Sep 10, 2025Form 4 · 10b5-1 | Simpson CurranChief Executive Officer | SellCommon Stock | 7.7K | $10.02 | $77.5K | 244.6K |